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Summary 
The prostaglandin endoperoxide H synthase isoform 
2, cyclooxygenase 2 (COX-2), is induced at high lev- 
els in migratory and other responding cells by pro- 
inflammatory stimuli. COX-2 is generally considered 
to be a mediator of inflammation. Its isoform, COX-1, 
is constitutively expressed in most tissues and is 
thought to mediate “housekeeping” functions. These 
two enzymes are therapeutic targets of the widely used 
nonsteroidal anti-inflammatory drugs (NSAIDs). To in- 
vestigate further the different physiologic roles of 
these isoforms, we have used homologous recombina- 
tion to disrupt the mouse gene encoding COX-2 
(Ptgs2). Mice lacking COX-2 have normal inflammatory 
responses to treatments with tetradecanoyl phorbol 
acetate or with arachidonic acid. However, they de- 
velop severe nephropathy and are susceptible to peri- 
tonitis. 
Introduction 
Aspirin, one of the oldest and most extensively used syn- 
thetic drugs in the pharmacopoeia, belongs to the class 
of drugs known as nonsteroidal anti-inflammatory drugs 
(NSAIDs). Examples of other more recently introduced 
NSAlDs in common usage include ibuprofen, naproxen, 
indomethacin, and sulindac. In addition to their acute anti- 
inflammatory and analgesic actions, NSAlDs have been 
demonstrated to be effective against chronic diseases. 
For example, small daily doses of aspirin can decrease 
platelet aggregation, thereby reducing the incidence of 
thrombotic heart attacks and strokes by up to 50% 
(Meade, 1992). In addition, long-term use of aspirin in both 
women and men is associated with a 40% decrease in 
risk for fatal colon carcinoma (Thun et al., 1991, 1993). 
Nevertheless, the deleterious side effects of NSAlDs can 
be significant. These include a high incidence of gastroin- 
testinal toxicity (Brooks and Day, 1991; Carson et al., 
1987) and, under certain conditions, damage to renal func- 
tion (Clive and Stoff, 1984). Indeed, renal problems for 
patients with a variety of diseases can become especially 
severe if prostaglandin synthesis is inhibited by NSAlDs 
(Whelton et al., 1990). The effects of NSAIDs, both thera- 
peutic and toxic, can be attributed to a decrease in the 
production of prostaglandins (Vane, 1971; Flower, 1974). 
The prostaglandins are a diverse group of autocrine and 
paracrine hormones that mediate many cellular and physi- 
ologic processes. Prostaglandin HP (PGH2) is an obligate 
intermediate in formation of the prostaglandins. Prosta- 
glandin synthase, an enzyme with two known isoforms, 
catalyzes formation of PGHz from arachidonic acid (AA). 
These prostaglandin synthases are the primary enzymatic 
targets for NSAlDs (Flower and Vane, 1972; Flower et al., 
1972; Dewitt et al., 1993). We refer to the two prostaglan- 
din synthase isoforms as cyclooxygenase 1 (COX-1) and 
cyclooxygenase 2 (COX-2); their respective genes in the 
mouse are prostaglandin synthase 1 (Pfgs7) and 2 (Ptgs2). 
COX-1 and COX-2 are similar in both amino acid sequence 
and enzymatic function (O’Banion et al., 1992; Ryseck et 
al., 1992; Fletcher et al., 1992; Hsi et al., 1994) although 
their physiologic functions are thought to be quite different 
(Smith et al., 1994). 
COX-1 is constitutively expressed in most tissues (Sim- 
mons et al., 1992; O’Neill and Ford-Hutchinson, 1993) but 
at different levels in various cell types. Enzyme expression 
usually remains atfairlyconstant levels, although dramatic 
changes can occur in certain cells after stimulation with 
growth factors or other agents (Dewitt, 1991; Smith et al., 
1993). lmmunofluorescence data indicate that COX-I is 
the isoform expressed in kidney, stomach, vascular 
smooth muscle (Smith et al., 1994), and platelets (Funk 
et al., 1991). 
COX-2 has a markedly different expression pattern. Nor- 
mally, the enzyme is undetectable in most tissues, but it 
can be expressed at high levels in macrophages and cer- 
tain other cell types after induction with a variety of sub- 
stances, including inflammatory mediators and mitogens 
(Lee et al., 1992; Fu et al., 1990; Evett et al., 1993; Kujubu 
et al., 1991; Masferreret al., 1992; Sanoet al., 1992; O’Sul- 
livan et al., 1992a, 1992b). The inhibition of COX-2 expres- 
sion by anti-inflammatory glucocorticoids lends further 
credence to a presumed role for COX-2 in inflammation 
(O’Banion et al., 1992; Kujubu et al., 1991; Kujubu and 
Herschman, 1992; Masferrer et al., 1992). COX-2 is also 
found to be up-regulated in human colorectal adenomas 
and adenocarcinomas (Eberhart et al., 1994). Other traits 
that distinguish PtgsP from Ptgsl are inhibition of Ptgs2 
transcription by interleukin-10 (Mertz et al., 1994) and 
transforming growth factor 81 (Reddy et al., 1994). 
In addition to the cellular traits that distinguish the two 
isoforms from one another, individual NSAlDs inhibit 
COX-1 and COX-2 in characteristically different ways. For 
example, the acetylation of Ser-530 in COX-1 by aspirin 
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irreversibly inactivates the enzyme (Humes et al., 1981; 
Rome and Lands, 1975; Rome et al., 1976; Roth et al., 
1983), while acetylation of the corresponding residue in 
COX-2 causes the enzyme to catalyze formation of 15- 
hydroxy-eicosatetraenoic acid instead of PGH, (Meade et 
al., 1993; O’Neill et al., 1994; Cromlish et al., 1994). Ibupro- 
fen acts as a reversible inhibitor approximatelyequipotent 
on either isoform, while 6-methoxy-naphthyl-acetic acid 
(the active metabolite of nambutone) preferentially inhibits 
COX-2 (Dewitt et al., 1993; Smith et al., 1994). COX-2 
inhibitors have anti-inflammatory properties with little gas- 
trointestinal ulceration (Masferrer et al., 1994; Futaki et 
al., 1994) while COX-1 inhibitors have anti-inflammatory 
properties but tend to cause gastrointestinal distress as 
aside effect (Brooks and Day, 1991; Clive and Stoff, 1984). 
The above findings have led to the view that the constitu- 
tively expressed enzyme, COX-1, is involved in producing 
prostaglandins for cellular “housekeeping” functions, in- 
cluding gastric cytoprotection, vascular homeostasis, and 
normal renal maintenance. The inducible enzyme, COX-2, 
is thought to be involved in inflammation, cellular differenti- 
ation, and mitogenesis (Dewitt et al., 1993). However, de- 
spite intense investigation of prostaglandin synthesis and 
function, clear models for the individual roles of COX-1 
and COX-2 remain elusive. It is therefore of great interest 
to investigate further the roles of the individual COX iso- 
forms in vivo. To do this, we have generated mice in which 
Ptgs2 has been disrupted by gene targeting and describe 
herein the consequences of the resulting lack of COX-2. 
Results 
Vector Construction and Gene Targeting 
The mouse PtgsP gene was isolated as a h bacteriophage 
clone containing a 16 kb fragment of Bglll-digested geno- 
mic DNA. This DNA fragment was obtained from the 
mouse strain 129-derived embryonic stem (ES) cell line 
El4TG2a. The probe used to identify the h clone was a 
408 bp fragment specific to exon 10 of Ptgs2 and was 
derived by polymerase chain reaction (PCR) amplification 
of mouse genomic DNA using primers made from the pub- 
lished sequence of Ptgs2. The single PCR fragment ob- 
tained was demonstrated by digestion with Clal and Ncol 
to be from Ptgs2 (data not shown); sites for these enzymes 
are not present in the corresponding Ptgsl region. A Pfgs2 
cDNA clone (O’Banion et al., 1992) was used as a probe 
to confirm the identity of the h clone. Successful amplifica- 
tions using primer sets specific to exons 1, 4, 7, 8, and 10 
of Pfgs2 were used to establish the identity of the genomic 
clone further and to distinguish it from Ptgsl (data not 
shown). 
Figure 1 B depicts the targeting construct used to inacti- 
vate Ptgs2 in the ES cell line El4TG2a. As illustrated, a 
neomycin resistance gene (Neo) has been inserted be- 
tween a 6.0 kb EcoRl fragment and a 1.8 kb BstXI-EcoRI 
fragment, both obtained from the 16 kb genomic clone of 
PtgsP. This insertion interrupts the coding sequence in 
exon 8 (Figure 1 B), thereby disrupting Ptgs2 (Figures 1A 
and 1C). In addition to the insertion, we introduced a 104 
2.6 Kb 
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Figure 1. Disruption of the Mouse PtgsZ 
(A) The endogenous Ptgs2 locus. The numbered closed boxes denote 
exons. The double arrow indicates the endogenous Sac1 fragment 
characteristic of the wild-type gene. B, Bx, E, S, and St indicate the 
Bglll, BstXI, EcoRI, Sacl, and Styl sites, respectively. 
(B) Targeting construct. Neo and TK indicate neomycin resistance and 
thymidine kinase genes, oriented as indicated by the arrows. The wavy 
line indicates plasmid sequence (not drawn to scale). A8 represents 
exon 8 after deletion of the region between the EcoRl and BstXl with 
subsequent insertion of Neo. A10 indicates the truncated exon 10. 
The most 5’EcoRI site in the construct comes from the h phage vector. 
(C)The targeted PtgsP locus with Neo disrupting exon 8. PCR primers 
used to identify targeted cell lines are shown as right and left arrow- 
heads. The double arrow indicates the Sacl fragment characteristic 
of the targeted PtgsP gene. 
(D) Autoradiogram from a Southern blot of mouse F2 genomic DNA 
digested with Sacl, showing the expected fragments for the wild-type 
(2.6 kb) and targeted alleles (3.8 kb) as indicated by the arrows. The 
blot was probed with a radiolabeled Sacl fragment from a cDNA of 
Ptgs2; this fragment includes exons 8 and 9 and a 5’ portion of exon 
10. ES denotes DNA from the parental ES cell line; (+I+), (+I-), and 
(-I-) denote tail DNA from wild-type, heterozygous, and homozygous 
mutant F2 mice, respectively. 
bp deletion in exon 8 that eliminated the nucleotides en- 
coding Tyr-371 and His-374, both crucial for COX activity 
(Shimokawa et al., 1990; Shimokawa and Smith, 1990). 
Nucleotide sequence data spanning the junction of the 
Neo gene with exon 8 were obtained and demonstrated 
that the sequence at the junction corresponds to PtgsP 
(data not shown). 
Of 192 G418-ganciclovir-resistant clones isolated, 11 
were determined to have undergone homologous recom- 
bination. This determination was made by PCR amplifica- 
tion of a fragment characteristic of the desired gene tar- 
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geting event. Cell lines having undergone the planned 
targeting event display a 2.0 kb PCR product when PCR 
is performed using the two primers illustrated in Figure 
1C. Genomic DNAs from the PCR-positive cell lines were 
digested with Sacl for Southern blot analysis. Targeted 
clones showed the expected presence of a 2.6 kb DNA 
fragment corresponding to the wild-type PfgsP allele and a 
3.8 kb DNA fragment corresponding to the targeted allele. 
Two targeted cell lines were injected into C57BL16J (B6) 
blastocysts. Both gave rise to male chimeric animals that, 
when mated to B6 females, subsequently passed the tar- 
geted allele to their Fl 129/86 offspring. Fl heterozygotes 
were interbred, and Southern blot analysis of genomic 
DNA from their F2 progeny showed the 2.6 kb and/or 3.8 
kb DNAfragments expected for the wild-type (+I+), hetero- 
zygous (+I-), and homozygous mutant (-/-) genotypes 
(Figure 1 D). 
Genotypic Ratios from Fl x Fl Matings 
Matings between heterozygous Fl animals produced F2 
progeny in the following numbers (wild type:heterozygous: 
homozygous): females, 15:31 :ll; males, 28:20:12. The 
genotypes of the female progeny did not differ from Men- 
delian expectations (X2, p > 0.5). However, males showed 
significant deviation from normal Mendelian ratios (x2, 
p < 0.001). 
Lipopolysaccharide Induction of Ptgs2 mRNA 
in Peritoneal Macrophages 
Pfgs2 is an inducible gene with only slight transcriptional 
activity in the absence of stimulation. Lipopolysaccharide 
(LPS) induction of macrophages normally elicits a marked 
increase in Ptgs2 mRNA levels resulting in increased 
PGE2 production (Lee et al., 1992). We therefore com- 
pared the responses of peritoneal macrophages from F2 
wild-type animals with F2 mutants homozygous for the 
gene disruption. The Northern blot in Figure 2A illustrates 
the levels of Pfgs2 mRNA that were detected in peritoneal 
macrophages from wild-type and homozygous F2 animals 
before and after induction with LPS. In the wild-type mac- 
rophages, the level of detectable mRNA (4.7 kb in size) 
increases 13-fold, as determined by densitometry. In the 
homozygous mutant macrophages, no mRNA of the nor- 
mal size is found, either before or after LPS treatment. 
However, a very low level of aberrant 6 kb transcript can 
be detected. This transcript also hybridizes to a Neo probe 
(data not shown) and represents an anomalous mRNA 
containing both Neo and PtgsP sequences. Thus, mutant 
macrophages synthesize no normal Ptgs2 mRNA before 
or after LPS induction. 
LPS Induction of COX-2 Protein 
in Peritoneal Macrophages 
To confirm further the inactivation of PtgsP in homozygous 
mutants, we measured the levels of cellular COX-2 protein 
by Western blot analysis. The Western blot in Figure 28 
illustrates the levels of enzyme in macrophages as de- 
tected by a polyclonal antibody specific to COX-2. COX-2 
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Figure 2. Expression of PtgsP mRNA and Protein from Macrophages 
before and after Induction with LPS 
(A) Autoradiogram from a Northern blot of total RNA isolated from 
macrophages induced (plus) or uninduced (minus) with LPS. The 
probe was made from a Sac1 fragment of a PtgsP cDNA (Oxford Bio- 
medical Research). (+I+) or (-I-) denotes RNA from a wild-type F2 
animal or a homozygous Pfgs2 disrupted animal, respectively. The 
Cox2 at the left indicates the position of COX-2 mRNA; mRNA sizes 
are indicated on the right. 
(B) A Western blot of total protein isolated from macrophages induced 
(plus) or uninduced (minus) with LPS. COX-2 was detected using a 
polyclonal antibody(Cayman Chemical) specific for that protein in con- 
junction with chemiluminescence. (+I+) or (-I-) denotes protein from 
awild-type F2animalora homozygousPtgsPdisruptedanima1, respec- 
tively. The approximate sizes of the glycosylated and unglycosylated 
COX-2 proteins are indicated on the right. 
to glycosylation) approximately 70-72 kDa in size (Pritch- 
ard et al., 1994). The wild-type macrophages show a 
greater than lo-fold increase in COX-2 levels after LPS 
treatment, as determined by densitometry. The homozy- 
gous mutant macrophages fail to show any immunoreac- 
tive COX-2 before or after LPS induction, as expected from 
the absence of PtgsP mRNA. We conclude that our gene 
targeting has abolished any detectable production of 
COX-2 by the Ptgs2 gene. In contrast, levels of COX-1 
in homozygous macrophages were unchanged in treated 
and untreated cells and were equivalent for both wild-type 
or homozygous mice (data not shown). 
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Figure 3. Synthesis of PGE*from Macrophages after induction of LPS 
The fold increase in PGEz levels from peritoneal macrophages after 
induction with LPS are depicted by the bars. This was calculated by 
dividing the levels after induction by the levels before induction. (+I+) 
and (-I-) denote data from wild-type and homozygous mutant F2 mice, 
respectively. 
LPS Induction of PGE2 Synthesis 
in Peritoneal Macrophages 
Synthesis of PGEp requires prior formation of PGH2 and 
thus provides a convenient measure of PGH2 production 
in macrophages. Figure 3 illustrates the results obtained 
by measurement of PGG levels from LPS-stimulated and 
LPS-unstimulated macrophages. Levels of PGE2 from 
wild-type macrophages rose an average of 10.8 (+ 0.5)- 
fold (n = 2) after stimulation with LPS. However, PGE2 
levels in theculturesof homozygous mutant macrophages 
were not significantly altered after treatment with LPS 
(0.05 [ + 0.35]-fold increase; n = 2). This provides further 
evidence that PtgsE has been completely inactivated by 
our gene disruption strategy. 
Inflammatory Responses after Treatment of the Ear 
with Tetradecanoyl Phorbol Acetate 
or Arachidonic Acid 
Swelling of the ear in response to tetradecanoyl phorbol 
acetate (TPA) or arachidonic acid (AA) are standard 
assays by which inflammation can be quantitated (Opas 
et al., 1985; Gad et al., 1986). Ear thickness is measured 
prior to exposure to the inflammatory agent and then at 




Figure 4. Response of Mice to the Inflam*matory Mediators TPA 
and AA 
Bar graph depicting the percentage increase in ear thickness after 
treatment with TPA and AA. (+I+) denotes data from wild-type F2 
animals; (-I-) denotes data from homozygous Ptgs.2 disrupted 
animals. 
is taken to be the 100% value (baseline), and the percent- 
age increase in thickness relative to the baseline value is 
then calculated. F2 wild-type mice exposed to TPA had 
an average increase in ear thickness of 91 + 10% (n = 
5), while homozygous mutant F2 mice had an increase of 
101 + 15% (n = 6; Figure 4). Similarly, wild-type F2 mice 
exposed to AA had an average increase in ear thickness 
of 93 f 12% (n = 7), while their F2 homozygous mutant 
counterparts had an increase of 88 + 13% (n = 7; Figure 
4). A two-tailed Student’s t test comparing wild-type and 
homozygous mutant animals demonstrates that both 
genotypes showed significant responses to the inflamma- 
tory mediators (p < 0.001). The responses to both TPA 
and AA did not differ between wild-type and homozygous 
mutant genotypes (p > 0.5). Thus, an active PtgsP gene 
is not essential for these inflammatory responses. 
Mortality and Renal Pathology in Homozygous 
Mutant Mice 
Survival ofweaned F2animals heterozygousfordisruption 
of PfgsP did not differ from that of F2 wild types. However, 
several homozygous mutant animals were found dead at 
approximately 8 weeks of age. To ascertain the likely 
cause of their death, we sacrificed seven homozygous 
mutants and seven wild-type mice at 6-l 6 weeks of age 
for comparative pathological analysis. 
General gross anatomical examination was made of 
both genotypes, and microscopic examination was done 
on skin, brain, eye, lungs, heart, liver, spleen, lymph 
nodes, kidneys, reproductive organs, and gastrointestinal 
tract. Significant and consistent genotype-related abnor- 
malities were observed in the kidneys of three of three 
g-week-old, three of three 8-week-old, and one of one 16- 
week-old mice homozygous for PtgsP disruption. 
Gross examination of kidneys from 8-week-old male ho- 
mozygous mutant mice revealed kidneys that were small 
and pale and that had a granular appearance on the capsu- 
lar surface. Kidneys from wild-type animals were normal 
in appearance. Light microscopic examination of kidneys 
from four wild-type males and three wild-type females re- 
vealed no histologic abnormalities (Figure 5A). In contrast, 
the kidneys of all adult homozygous animals examined 
(four males and three females) had lesions of mild to 
marked severity. In its mildest form, the nephropathy was 
characterized by multifocal areas of abnormal subcapsu- 
lar parenchyma comprised of small immature glomeruli 
and tubules, consistent with nephron hypoplasia (Figure 
58). In some cases, the cortex appeared thinned, and the 
number of glomeruli were reduced in comparison with 
wild-type kidneys. Glomeruli not within the hypoplastic 
zone were frequently found to be enlarged. Other patho- 
logical findings included cortical areas of tubular atrophy 
and regeneration, protein and cellular casts within tubular 
lumens, tubular dilation, interstitial inflammation and fi- 
brosis, and papillary mineralization. In general, these 
changes were more severe in the male than in the female 
homozygous mutants, and they increased in severity with 
advancing age. The 8-week-old homozygous mutant 
mouse kidneys had a few small scattered foci of tubular 
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Figure 6. Severe Kidney Disease in Mature Adult Homozygous Mu- 
tant Mice 
Renal cortex from a 16-week-old male homozygous mutant mouse 
showing segmental (small arrow) and global (large arrow) glomerular 
sclerosis, as well as tubule atrophy and interstitial fibrosis. Note the 
subcapsular hypoplastic glomeruli. Stained with hematoxylin and 
eosin. The capsular margin is at the top. 
Figure 5. Comparison of Renal Cortex from Wild-Type and PfgsP Dis- 
rupted Mice 
(A) Renal cortex from an 8-week-old wild-type F2 male mouse. The 
box encloses a normal tubule. 
(B) Renal cortex from an 8-week-old homozygous mutant mouse photo- 
graphed at the same magnification as (A) and showing subcapsular 
glomerular hypoplasia (denoted by small upward-pointing arrows) and 
hypertrophy of deeper cortical glomeruli (indicated by the large down- 
ward-pointing arrow). The box encloses a hypertrophied tubule. 
Stained with hematoxylin and eosin. 
atrophy and interstitial fibrosis that were not present in 
the g-week-old homozygous mutant mice. The single ho- 
mozygous mutant male that survived to necropsy at 16 
weeks of age had severe focal interstitial fibrosis and tubu- 
lar atrophy associated with focal segmental and global 
glomerular sclerosis (Figure 6). Renal arteries and arteri- 
oles were unremarkable. 
To ascertain the general timeframe in which the renal 
pathology developed, a litter of 3-day-old pups was sacri- 
ficed and their kidneys examined. The renal histology of 
the COX-2-deficient mice did not differ from that of wild 
type. In particular, the 3-day-old homozygous mice had a 
normal subcapsular zone of immature nephrogenic tissue 
and normal numbers of glomeruli in the kidney cortex. 
This is in contrast with the g-week and older homozygous 
mice, which showed abnormal nephron hypoplasia in the 
subcapsular region and abnormally low numbers of glo- 
meruli in the kidney cortex. Thus, COX-2-deficient mice 
show postnatal developmental abnormalities in their kid- 
neys that then progressively deteriorate with increas- 
ing age. 
Peritoneal Pathology in Some Homozygous 
Mutant Mice 
Of the three Ptgs2 homozygous mice 8 weeks of age (the 
age at which death in homozygous mutants was most fre- 
quently observed), two were found to have suppurative 
100 pm -- 
Figure 7. Marked Inflammatory Response to 
Bacterial Invasion of the Peritoneum 
(A) Peritonitis involving the gut wall of a male 
a-week-old homozygous mutant mouse. Puru- 
lent exudate (denoted by the arrow), focal acute 
inflammation of the muscularis, and focal accu- 
mulation of bacteria (see inset box). Stained 
with hematoxylin and eosin. 
(6) Higher magnification of the rod-like bacteria 
(indicated by the arrows) from the inset box in 
(A). Stained with hematoxylin and eosin. 
(C) Leukocytic infiltration of the bowel wall in an 
a-week-old homozygous mouse. Submucosal 
edema (indicated by the asterisk) associated 
with a band of intense neutrophil infiltration (in- 
dicated by the closed arrows) and cellular de- 
generation. Note the bacterial colonies near 
the serosal surface (indicated by open arrows). 
Stained with hematoxylin and eosin. 
peritonitis. No abnormalities were observed in any of the 
wild-type mice. The homozygous male had acute suppura- 
tive peritonitis, while the female had chronic suppurative 
peritonitis. Accompanying gross lesions of the abdominal 
cavity were found. The female had multiple adhesions 
among the abdominal organs that corresponded micro- 
scopically to abscesses and chronic fibrous inflammatory 
tissue bridging lobes of the liver and loops of the bowel. 
The peritonitis involved multiple abdominal organs and 
was characterized by both serosal exudation and focal 
necrotizing acute inflammation that had penetrated into 
the superficial tissues of viscera and retroperitoneum 
(Figure 7A). Submucosal edema of the bowel wall was 
observed, and inflammatory infiltrates were composed 
predominantly of neutrophils with conspicuous leukocy- 
toclasia (Figure 7C). Colonies of bacteria were visible in 
some of the inflammatory exudate and within the inflamed 
tissue (Figures 76 and 7C). Both mice with peritonitis had 
myeloid hyperplasia in their spleens. The female also had 
marked lymphoplasmacytic hyperplasia of the mesenteric 
lymph node. 
One qualification of these observations must be men- 
tioned. The female mutant with chronic suppurative perito- 
nitis had been previously treated intraperitoneally with 
sterile thioglycolate to harvest macrophages. None of the 
several wild-type mice injected at the same time displayed 
this pathology. In addition, the homozygous male, which 
had not been treated with thioglycolate, displayed a more 
severe peritonitis. Thus, it seems unlikely that the injection 
caused the peritonitis in the homozygous female. 
Discussion 
Abnormal Mendelian Ratios of Male F2 Progeny 
The preponderance of wild-type genotypes in the male but 
not female progeny of heterozygous x heterozygous Fl 
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parents suggests that the lack of functional Ptgs2 nega- 
tively affects either the number of embryos fertilized by 
male sperm carrying the defect or the fitness of the em- 
bryos or neonates carrying one or more copies of the mu- 
tant allele. Some indication that the possible defect is prior 
to implantation is the finding that equal numbers of males 
(60) and females (57) reached weaning age (20 days) de- 
spite the differences in genotypic ratios of the male and 
female weanlings. More investigation of this anomaly will 
be necessary to reach any firm conclusions. It will also 
be necessary to establish whether later generations of 
mice retain the abnormal ratios of male progeny. 
Normal Inflammatory Responses in Ptgs2 
Homozygous Mutant Mice 
Mice homozygous for the targeted ftgs2 disruption com- 
pletely lack the normal induction of PtgsP mRNA, protein, 
and prostaglandin synthesis by the proinflammatory agent 
LPS. It is therefore surprising to find that the lack of COX-2 
and PGEp synthesis does not affect the inflammatory re- 
sponse of the ear to TPA, which is known to be a potent 
inducer of COX-2. Similarly, AA, the substrate for COX, 
also induces a normal response in the mutant homozy- 
gotes. These results clearly demonstrate that COX-2 is 
not essential for these inflammatory responses, since its 
complete absence does not decrease the inflammatory 
response of the ear to TPA or AA. 
We do not at present understand the etiology of the 
peritonitis in two of seven PtgsP homozygous mutant mice. 
However, it is important to note that the affected mice 
homozygous for PfgsP disruption showed classic inflam- 
matory reactions to the invasion of the peritoneum by bac- 
teria. Specifically, the COX-2-deficient mice showed ne- 
crosis and associated inflammation, fibrinous adhesions, 
and infiltration of leukocytes; these are conditions that 
would be expected in a normal inflammatory response to 
bacterial infection. This indicates that Ptgs2 is not essen- 
tial for these inflammatory responses, although COX-2 
may be needed either for the prevention or the ameliora- 
tion of the infections. 
Kidney Pathology in Mice as a Result 
of PtgsP Inactivation 
The inactivation of Ptgs2 by gene targeting is highly infor- 
mative in terms of defining those organs in which COX-2 
is essential. The pathology of homozygous mutant mice 
clearly demonstrates that the most severe effects related 
to disruption of Pfgs2 are kidney abnormalities and possi- 
bly the occurrence of peritonitis in some animals. 
Recent investigations have demonstrated that COX-2 
levels in rat mesangial kidney cells increase in response 
to endothelin-I and serotonin (Kester et al., 1994; Stroebel 
and Goppelt-Struebe, 1994). Salt-restricted diets also alter 
the intrarenal distribution of COX-2 and cause an increase 
in its expression (Harris et al., 1994). These observations 
make it less surprising that kidneys of homozygous mutant 
mice older than 6 weeks (both male and female) showed 
severe pathology. 
Kidney development is not complete in mice at birth but 
continues postnatally for several weeks. The observation 
of normal renal histology in 3-day-old mice homozygous 
for PtgsP disruption but severe abnormalities in B-week or 
older homozygous mice suggests a postnatal maturation 
arrest in the subcapsular nephrogenic zone. This zone 
normally continues to generate nephrons during the post- 
natal period. Such an arrest would result in a subcapsular 
zone of hypoplastic glomeruli, which in turn would cause a 
compensatory hypertrophy of those glomeruli and tubules 
that had developed prior to the maturation arrest. The glo- 
merular sclerosis and associated tubulointerstitial injury 
observed in the 16-week-old homozygous mutant could 
then be explained as resulting from a work overload on 
the reduced number of functional nephrons. 
Thus, a possible explanation for these findings is that 
the absence of COX-2 in the homozygous mutant mice 
impairs postnatal differentiation within the subcapsular 
nephrogenic zone. In kidneys with reduced numbers of 
nephrons, those nephrons that are present must increase 
their workload. This leads first to hypertrophy and eventu- 
ally to glomerular sclerosis (Brenner, 1985). This type of 
glomerular compensatory hypertrophy and subsequent 
sclerosis occur following experimental reduction in the 
number of nephrons in utero (Gilbert et al., 1991) or after 
birth (Brenner, 1985). It is most severe when the reduction 
in nephrons occurs early (Celsi et al., 1986). 
It is interesting to note the similarities between our find- 
ings and those seen in oligomeganephronia, a human con- 
genital renal disease characterized by small kidneys with 
reduced numbers of nephrons. This disease occurs as 
a consequence of too few nephrons developing during 
nephrogenesis (McGraw et al., 1984). The glomeruli and 
tubules are hypertrophied and develop progressive focal 
segmental glomerularsclerosis, probably because of func- 
tional overload (McGraw et al., 1984). 
In contrast with the severe pathology seen after disrup- 
tion of both gene copies in homozygous mice, inactivating 
a single copy of PfgsP in the heterozygous animals did 
not lead to any renal or peritoneal pathology. 
Concluding Statements 
The current findings in the animals lacking the inducible 
enzyme COX-2 can be summarized as follows. The ani- 
mals show no innate gastrointestinal pathology, but their 
kidneys show abnormalities that cause a progressive dete- 
rioration as the animals age. Their inflammatory re- 
sponses to TPA and AA do not differ from those of wild-type 
animals, and they have normal inflammatory responses 
to bacterial invasion of the peritoneum. 
Langenbach et al. (1995 [this issue of Cc/J) have de- 
scribed animals lacking the constitutive enzyme COX-1. 
In brief, these animals have no gastrointestinal abnormali- 
ties, but the female homozygotes have few live births when 
mated to male homozygotes. The animals have a de- 
crease in AA-induced platelet aggregation, and their in- 
flammatory responses to AA (but not to TPA) are reduced. 
These joint observations suggest the need to reappraise 
some of the current views concerning the detailed func- 
tions of the two COX isoforms. Genetic experiments of 
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the type we have described are unequivocal in their ability 
to distinguish the cellular and physiological effects of the 
complete and lifelong absence of each COX isoform with- 
out any unintentional inhibition of the other. In addition, 
while compensatory adaptations in response to the loss 
of Ptgs2 may have modified certain elements of the pheno- 
type, the identification and study of these adaptive re- 
sponses are likely to yield new insights into pathways with 
which COX-2 interacts. The data that can be derived from 
these animals should consequently be of great value for 
the study of the two COX isoforms and also to research 
directed at the development of improved NSAIDs. 
Experimental Procedures 
Cloning the PGH Synthase 2 Gene and Construction 
of the Targeting Vector 
Southern blot analysis of genomic DNA from strain 129 mice indicated 
that a PtgsP-specific probe (derived by PCR) hybridized to a 18 kb Bglll 
fragment. Two regions in exon 10 of the murine PtgsP gene (Fletcher et 
al., 1992), which are highly conserved between species but not be- 
tween COX-1 or COX-2, were chosen for PCR primers to generate 
the PtgsP probe. The primers used were from the 5’ region of exon 10 
(GAGAAGGAAATGGCTGCACA) and the 3’ region of exon 10 coding 
sequence (TTACAGCTCAGTTGAACGCCT); the resulting probe cor- 
responds to amino acid residues450-585 (Fletcher et al., 1992). Geno- 
mic DNA was isolated from E14TG2a mouse ES cells (Hooper et al., 
1987) and digested with Bglll. Fragments from lo-20 kb in length 
were isolated and used to make a library in h phage Charon 35. A 
murine Ptgs2 cDNA probe (provided by Dr. D. Young, University of 
Rochester) was also used in the screening process. Clones covering 
the entire gene coding sequence were isolated, and two EcoRl frag- 
ments that contain all but the most 3’ portion of the gene were sub- 
cloned. A 8.0 kb EcoRl fragment (containing exon 1 through the 5’ 
part of exon 8) and a 1.8 Kb BstXI-EcoRI fragment (containing a 3’ 
portion of exon 8, exon 9, and a 5’part of exon 10) were used to create 
the targeting vector (see Figures 1 A and 1 B). 
Cell Culture, Electroporation, and Selection 
BK4cells (asubcloneof E14TG2a, provided by Dr. B. Koller, University 
of North Carolina at Chapel Hill) were cultured on murine embryonic 
fibroblasts in DMEM-H (Life Technologies) supplemented with 15% 
fetal bovine serum (Life Technologies), 100 pM P-mercaptoethanol, 
and 2 mM L-glutamine. The cells were trypsinized and resuspended 
in 0.4 ml of DMEM. Electroporation was carried out in the presence 
of 2-5 nM targeting construct DNA that had been linearized with Sacll; 
a 1 s discharge from a 200 I.IF capacitor charged to 300 V was used. 
Selection with G418 and ganciclovir was carried out as described by 
Mansour et al. (1988). 
Half of each clone was picked using a micropipette and placed in 
a 24-well tissue culture plate overnight. The next day, the colony was 
trypsinized and expanded for use or was frozen in 50% serum, 40% 
DMEM, and 10% DMSO at -8OOC. The other half of the clone was 
utilized for genotypic PCR analysis. 
Genotype Analysis by PCR and Southern Blotting 
Potential recombinant clones were initially screened by recording the 
presenceof a PCR product diagnostic for acorrect homologous recom- 
bination event (Kim and Smithies, 1988). The two primers used were 
derived from the Neo gene (ACGCGTCACCTTAATATGCG) and from 
a 3’ region of exon 10 that was not included in the targeting construct 
(AGATTGTTGTCAGTATCTGCC) (see Figure 1C). DNA from clones 
that had undergone homologous recombination (as judged by the am- 
plification of the correct PCR fragment) were then used for Southern 
blot analysis to confirm that PtgsP had been disrupted. 
Genotypes of mice were determined using DNA isolated from tails. 
Genomic DNA totaling 8-10 Kg was digested with Sacl overnight and 
applied to a 0.8% agarose gel. After separation using agarose gel 
electrophoresis, the DNA was transferred to Hybond nylon membrane. 
Membranes were probed with a 2.1 kb Sacl fragment from the Ptgs2 
cDNA clone, labeled with 32P. The Sacl cDNA probe used is contiguous 
with exons 8 and 9 and the 5’portion of exon 10. Membranes were then 
washed and exposed overnight to Kodak XAR film with an intensifying 
screen. 
Microinjection and Derivation of Mutant Mice 
Cells from two independent targeting events were microinjected into 
86 host blastocysts and implanted in pseudopregnant female recipi- 
ents to generate chimeric mice. Two male mice transmitted the 129 
genome to their progeny, and both were bred to B6 females. The 
heterozygous Fl progeny carrying the disrupted Ptgs2 gene were then 
interbred to give F2 mice, which were used for further studies. 
Induction of Macrophages with LPS and Measurement 
of PGE* Levels 
Macrophages were isolated by peritoneal lavage using 3 x 5 ml of 
sterile cold RPM1 1640 medium. Resident macrophages were seeded 
1 x IO7 to 1.5 x 10’ cells per 60 mm dish and then placed in a 
humidified incubator with 5% CO, for 2 hr. Cells that attached to the 
plate were counted using an eyepiece micrometer. Medium was re- 
moved, and the cells were washed with serumless medium. Cells were 
then incubated in medium containing 10 VM AA for 30 min. PGE? 
production was measured using a competitive radioimmunoassay 
(Amersham). 
Northern Blotting of Macrophages Induced with LPS 
Total RNA was isolated from plated macrophages using TRlzol (Life 
Technologies) as recommended by the manufacturer. Each sample 
(5 Kg) was electrophoresed in a 2.2 M formaldehyde-l% agarose gel, 
transferred to Hybond nylon membrane, and probed using a 2.1 kb 
Sacl fragment from the PtgsP cDNA clone, labeled with 32P. The mem- 
brane was then washed and exposed overnight to Hyperfilm MP with 
an intensifying screen. 
Western Blotting of Macrophages Induced with LPS 
Cells were washed with ice-cold PBS, lysed in sample buffer (100 mM 
Tris-HCI [pH 6.8],8% SDS, 6% 2-mercaptoethanol, 0.05% bromophe- 
nol blue, 20% glycerol), and boiled. Protein (5 wg) was separated by 
SDS-PAGE and transferred onto Hybond-ECL nitrocellulose. Mem- 
branes were blocked for 1 hr using 5% nonfat milk in Tris-buffered 
saline with 0.1% Tween 20 (TBST). After washing with TBST, blots 
were incubated overnight with a rabbit antibody against murine COX-2 
(Cayman Chemical) or COX-I (Morita et al., 1995) in TBST with 1% 
nonfat milk. Blots were again washed to remove unbound anti-COX-2 
or anti-COX-1 antibody and subsequently incubated with anti-rabbit 
IgG horseradish peroxidase-linked secondary antibody (Boehringer 
Mannheim) in TBST with 1% skim milk for 1 hr. Chemiluminescence 
was used to expose Hyperfilm-ECL according to the instructions of 
the manufacturer (Amersham). 
Mouse Ear Inflammation Assay 
AA (2 mg per 10 ~1) or TPA (1 pg per 10 ~1) in acetone was applied 
to the inside of the left ear and 10 pl of acetone was applied to the 
rightearasdescribed byopasetal. (1985). Earswellingwas measured 
after 2 hr or 7 hr for AA or TPA, respectively (Gad et al., 1986). 
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